Detection of a transient R292K mutation in influenza a/H3N2 viruses shed for several weeks by an immunocompromised patient

Journal of Clinical Microbiology

Volumn 53, Issue 4, 2015, Pages 1415-1418

  Babady, N Esther ^a   Laplante, Jennifer M ^b   Tang, Yi Wei ^a   St George, Kirsten ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; OSELTAMIVIR; VANCOMYCIN; ZANAMIVIR; ANTIVIRUS AGENT; SIALIDASE;

ABDOMINAL PAIN; ADENOVIRIDAE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BLOODY DIARRHEA; CASE REPORT; CAUSE OF DEATH; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; HERPES VIRUS INFECTION; HUMAN; HUMAN HERPESVIRUS 6; IMMUNOCOMPROMISED PATIENT; INFLUENZA A (H3N2); INFLUENZA VIRUS A H3N2; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; PYROSEQUENCING; R292K GENE; SINGLE NUCLEOTIDE POLYMORPHISM; THORAX RADIOGRAPHY; TREATMENT RESPONSE; VIRUS LOAD; VIRUS SHEDDING; WEIGHT REDUCTION; GENE EXPRESSION REGULATION; GENETICS; INFLUENZA; INFLUENZA A VIRUS (H3N2); MUTATION; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY;

INFLUENZA A VIRUS;

ANTIVIRAL AGENTS; GENE EXPRESSION REGULATION, VIRAL; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MUTATION; NEURAMINIDASE; OSELTAMIVIR; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VIRUS SHEDDING;

EID: 84925268714     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02845-14     Document Type: Article

References (27)

1. Babady NE, Mead P, Stiles J, Brennan C, Li H, Shuptar S, Stratton CW, Tang YW, Kamboj M. 2012. Comparison of the Luminex xTAG RVP Fast assay and the Idaho Technology FilmArray RP assay for detection of respiratory viruses in pediatric patients at a cancer hospital. J Clin Microbiol 50:2282-2288. http://dx.doi.org/10.1128/JCM.06186-11.
2. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ, Klimov AI. 2005. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet 366:1175-1181. http://dx.doi.org/10.1016/S0140-6736(05)67338-2.
3. Deyde VM, Sheu TG, Trujillo AA, Okomo-Adhiambo M, Garten R, Klimov AI, Gubareva LV. 2010. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother 54:1102-1110. http://dx.doi.org/10.1128/AAC.01417-09.
4. Deyde VM, Okomo-Adhiambo M, Sheu TG, Wallis TR, Fry A, Dharan N, Klimov AI, Gubareva LV. 2009. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res 81:16-24. http://dx.doi.org/10.1016/j.antiviral.2008.08.008.
5. Laplante JM, Marshall SA, Shudt M, Van TT, Reisdorf ES, Mingle LA, Shult PA, St George K. 2009. Influenza antiviral resistance testing in New York and Wisconsin, 2006 to 2008: methodology and surveillance data. J Clin Microbiol 47:1372-1378. http://dx.doi.org/10.1128/JCM.01993-08.
6. Department of Communicable Disease Surveillance and Response, World Health Organization. 2002. WHO manual on animal influenza diagnosis and surveillance. WHO/CDS/CSR/NCS/2002.5, rev 1. World Health Organization, Geneva, Switzerland.
7. Hurt AC, Okomo-Adhiambo M, Gubareva LV. 2012. The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors. Methods Mol Biol 865:115-125. http://dx.doi.org/10.1007/978-1-61779-621-0-7.
8. World Health Organization. 2012. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012. Wkly Epidemiol Rec 87:369-374.
9. Nichols WG, Guthrie KA, Corey L, Boeckh M. 2004. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 39:1300-1306. http://dx.doi.org/10.1086/425004.
10. Moscona A. 2005. Neuraminidase inhibitors for influenza. N Engl J Med 353:1363-1373. http://dx.doi.org/10.1056/NEJMra050740.
11. Ferraris O, Kessler N, Lina B. 2005. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res 68:43-48. http://dx.doi.org/10.1016/j.antiviral.2005.07.004.
12. Colman PM. 1994. Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci 3:1687-1696. http://dx.doi.org/10.1002/pro.5560031007.
13. Colman PM, Varghese JN, Laver WG. 1983. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 303:41-44. http://dx.doi.org/10.1038/303041a0.
14. Collins PJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, Skehel JJ, Martin SR, Hay AJ, Gamblin SJ. 2008. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 453:1258-1261. http://dx.doi.org/10.1038/nature06956.
15. Moscona A. 2009. Global transmission of oseltamivir-resistant influenza. N Engl J Med 360:953-956. http://dx.doi.org/10.1056/NEJMp0900648.
16. Abed Y, Baz M, Boivin G. 2006. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 11:971-976.
17. McKimm-Breschkin JL. 2012. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses 7(Suppl 1):S25-S36. http://dx.doi.org/10.1111/irv.12047.
18. Varghese JN, McKimm-Breschkin JL, Caldwell JB, Kortt AA, Colman PM. 1992. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14:327-332. http://dx.doi.org/10.1002/prot.340140302.
19. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. 1997. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 71:3385-3390.
20. Tai CY, Escarpe PA, Sidwell RW, Williams MA, Lew W, Wu H, Kim CU, Mendel DB. 1998. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 42:3234-3241.
21. Babu YS, Chand P, Bantia S, Kotian P, Dehghani A, El-Kattan Y, Lin TH, Hutchison TL, Elliott AJ, Parker CD, Ananth SL, Horn LL, Laver GW, Montgomery JA. 2000. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 43:3482-3486. http://dx.doi.org/10.1021/jm0002679.
22. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N, Kawaoka Y. 2004. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364:759-765. http://dx.doi.org/10.1016/S0140-6736(04)16934-1.
23. Stephenson I, Democratis J, Lackenby A, McNally T, Smith J, Pareek M, Ellis J, Bermingham A, Nicholson K, Zambon M. 2009. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 48:389-396. http://dx.doi.org/10.1086/596311.
24. Piralla A, Gozalo-Marguello M, Fiorina L, Rovida F, Muzzi A, Colombo AA, Alessandrino PE, Baldanti F. 2013. Different drug-resistant influenza A(H3N2) variants in two immunocompromised patients treated with oseltamivir during the 2011-2012 influenza season in Italy. J Clin Virol 58:132-137. http://dx.doi.org/10.1016/j.jcv.2013.06.003.
25. Tamura D, Nguyen HT, Sleeman K, Levine M, Mishin VP, Yang H, Guo Z, Okomo-Adhiambo M, Xu X, Stevens J, Gubareva LV. 2013. Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment. Antimicrob Agents Chemother 57:6141-6146. http://dx.doi.org/10.1128/AAC.01364-13.
26. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, Sheu TG, Xu X, Klimov AI, Gubareva LV. 2010. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother 54:1834-1841. http://dx.doi.org/10.1128/AAC.01608-09.
27. Laplante J, St George K. 2014. Antiviral resistance in influenza viruses: laboratory testing. Clinics Lab Med 34:387-408. http://dx.doi.org/10.1016/j.cll.2014.02.010.